Brii Biosciences Ltd (2137)

Currency in HKD
1.97
-0.10(-4.83%)
Closed·
2137 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
2137 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.942.09
52 wk Range
0.803.09
Key Statistics
Bid/Ask
2.00 / 1.99
Prev. Close
2.07
Open
2.09
Day's Range
1.94-2.09
52 wk Range
0.8-3.09
Volume
5.46M
Average Volume (3m)
4.88M
1-Year Change
113.4%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2137 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.03
Downside
-47.73%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low Price / Book multiple

Brii Biosciences Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Brii Biosciences Ltd Company Profile

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.

Compare 2137 to Peers and Sector

Metrics to compare
2137
Peers
Sector
Relationship
P/E Ratio
−2.7x−19.4x−0.5x
PEG Ratio
0.010.290.00
Price/Book
0.5x6.7x2.6x
Price / LTM Sales
27.3x19.2x3.3x
Upside (Analyst Target)
−47.7%−1.3%43.5%
Fair Value Upside
Unlock−15.6%6.9%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 1.03
(-47.73% Downside)

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
-0.31 / -0.27
Revenue / Forecast
27.78M / --
EPS Revisions
Last 90 days

2137 Income Statement

FAQ

What Stock Exchange Does Brii Biosciences Trade On?

Brii Biosciences is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Brii Biosciences?

The stock symbol for Brii Biosciences is "2137."

What Is the Brii Biosciences Market Cap?

As of today, Brii Biosciences market cap is 1.42B.

What Is Brii Biosciences's Earnings Per Share (TTM)?

The Brii Biosciences EPS (TTM) is -0.70.

From a Technical Analysis Perspective, Is 2137 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Brii Biosciences Stock Split?

Brii Biosciences has split 0 times.

How Many Employees Does Brii Biosciences Have?

Brii Biosciences has 98 employees.

What is the current trading status of Brii Biosciences (2137)?

As of 07 Aug 2025, Brii Biosciences (2137) is trading at a price of 1.97, with a previous close of 2.07. The stock has fluctuated within a day range of 1.94 to 2.09, while its 52-week range spans from 0.80 to 3.09.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.